The estimated Net Worth of Lloyd P. Johnston is at least $1.41 Million dollars as of 4 January 2023. Lloyd Johnston owns over 9,784 units of Selecta Biosciences Inc stock worth over $233,653 and over the last 8 years he sold SELB stock worth over $119,083. In addition, he makes $1,055,540 as Chief Operating Officer and Senior Vice President - Research & development at Selecta Biosciences Inc.
Lloyd has made over 12 trades of the Selecta Biosciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 9,784 units of SELB stock worth $11,056 on 4 January 2023.
The largest trade he's ever made was exercising 44,871 units of Selecta Biosciences Inc stock on 11 February 2021 worth over $28,269. On average, Lloyd trades about 6,051 units every 87 days since 2016. As of 4 January 2023 he still owns at least 265,515 units of Selecta Biosciences Inc stock.
You can see the complete history of Lloyd Johnston stock trades at the bottom of the page.
Dr. Lloyd P. Johnston serves as Chief Operating Officer, Senior Vice President - Research & development of the Company. He has served as our Chief Operating Officer and Senior Vice President, Research and Development since January 2014. Dr. Johnston served as Selecta’s Senior Vice President of Pharmaceutical Research, Development and Operations from 2011 to 2013 and Vice President of Pharmaceutical Research from July 2008 to 2011. Prior to joining Selecta, Dr. Johnston was Vice President of Operations for Alkermes, Inc. from 2004 to 2008, and served in several roles, including Director of Manufacturing, from 1999 to 2004, with responsibility for process development, scale-up, and clinical manufacturing for pulmonary and sustained release injectable products, as well as leadership of Alkermes’ manufacturing facility in Chelsea, MA. At Alkermes, Dr. Johnston was also a project leader and member of Steering Committees for numerous products through various stages of development from Phase 1 through registration. Dr. Johnston was an original member of Advanced Inhalation Research Inc., or AIR, a private company formed in 1998 and acquired by Alkermes in 1999. Prior to joining AIR, Dr. Johnston was a lecturer in the Department of Chemical Engineering at the University of New South Wales in Sydney, Australia. He received his B.Sc. in Chemical Engineering from Queen’s University in Ontario, Canada, and his M.S. and Ph.D. in Chemical Engineering from MIT.
As the Chief Operating Officer and Senior Vice President - Research & development of Selecta Biosciences Inc, the total compensation of Lloyd Johnston at Selecta Biosciences Inc is $1,055,540. There are 1 executives at Selecta Biosciences Inc getting paid more, with Carsten Brunn having the highest compensation of $1,986,500.
Lloyd Johnston is 51, he's been the Chief Operating Officer and Senior Vice President - Research & development of Selecta Biosciences Inc since . There are 10 older and 6 younger executives at Selecta Biosciences Inc. The oldest executive at Selecta Biosciences Inc is Patrick Zenner, 73, who is the Independent Director.
Lloyd's mailing address filed with the SEC is C/O SELECTA BIOSCIENCES, INC., 65 GROVE STREET, WATERTOWN, MA, 02472.
Over the last 8 years, insiders at Selecta Biosciences Inc have traded over $10,638,154 worth of Selecta Biosciences Inc stock and bought 37,612,684 units worth $162,669,477 . The most active insiders traders include Timothy A Springer, Advisors Llc Orbi Med Capit..., and Carl L Gordon. On average, Selecta Biosciences Inc executives and independent directors trade stock every 23 days with the average trade being worth of $300,312. The most recent stock trade was executed by Carsten Brunn on 25 September 2023, trading 2,932 units of SELB stock currently worth $3,108.
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Selecta Biosciences Inc executives and other stock owners filed with the SEC include: